Mark Rosenthal

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine · 2004 · 5.7K citations

Reference Ranges for Spirometry Across All Ages

Sanja Stanojevic, Angie Wade, Janet Stocks et al. · American Journal of Respiratory and Critical Care Medicine · 2007 · 686 citations · Full text

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

Tracy T. Batchelor, Paul Mulholland, Bart Neyns et al. · Journal of Clinical Oncology · 2013 · 585 citations · Full text

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

Scott N. Holden, Sabine Eckhardt, R. Basser et al. · Annals of Oncology · 2005 · 306 citations · Full text

Medicine, Pharmacology, Pathology +6

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

Ian F. Tannock, Karim Fizazi, Camilla Thellenberg Karlsson et al. · The Lancet Oncology · 2013 · 285 citations

Aflibercept Versus Placebo, Urology, Oncology +7